Google
XAIR Stock Price & Analysis — Beyond Air Inc (Healthcare >> Medical Devices)
XAIR FAQ
What is XAIR's ROE?
Beyond Air Inc reports a Return on Equity (ROE) of -542.75%.
What is XAIR's dividend yield?
Beyond Air Inc offers a dividend yield of 0.00%.
What is XAIR's Quality Score?
Our AI rates XAIR's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy XAIR?
Our AI Timing Score for XAIR is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does XAIR belong to?
Beyond Air Inc is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange
XAIR AI Analysis Summary
Our AI summary for XAIR: Beyond Air Inc (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 0.00, ROE of -542.75%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 5.69
Price
-0.49
(-7.93%)
Day Change
|
|
|---|
XAIR, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.69 |
| PBV / Sector |
0.38 / 4.62
GREAT
|
| Earning Per Share | -80.11 |
| PE / Sector |
N/A / 32.46
|
| PEG or PE/Growth / Sector |
N/A / 0.50
|
| Average 1M Daily Value |
0.28 M
GREAT
|
| Average 1W Daily Value |
0.70 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-06 08:00:55 |
| Symbol | XAIR |
| Name | BEYOND AIR INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 0.72 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2.36 / 20,302.66 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 900 Stewart Avenue, Garden City, NY, United States, 11530
Phone: 516 665 8200
Website: https://www.beyondair.net
Employees: 54
Sector: Healthcare >> Medical Devices
Description: Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
